Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease
Inflammatory Bowel Diseases · 2023
DOI: 10.1093/ibd/izac079 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Joshua Y Kwon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Hepatitis B, Hepatitis B Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Background
Owing to the use of immunosuppressive agents, patients with inflammatory bowel disease (IBD) have an increased risk of vaccine preventable diseases, including infection with hepatitis B virus (HBV). Heplisav-B, an FDA-approved vaccine, is more effective (90% to 100%) than Engerix-B (70.5% to 90.2%) at inducing immunity to HBV in clinical studies. Available data on efficacy of Heplisav-B vaccine in patients with IBD are limited.
Methods
This retrospective observational study included patients age 18 years and older with ulcerative colitis (UC) or Crohn’s disease (CD) who received 1 or 2 doses of Heplisav-B vaccine and had postvaccination serologic testing. Prior to immunization, all participants were seronegative for HBsAb antibodies (HBsAb) measured as <10 IU/mL. Postvaccination HBsAb of ≥10 IU/mL was considered successful vaccination. Patient demographics, disease characteristics, and medications were abstracted.
Results
One hundred six patients were included in the analysis. Median age was 43 years, and 44 (42%) were female. Thirty-nine patients (37%) had UC, whereas 67 (63%) had CD. Eighty-three patients (78.3%) had active immunity after vaccination with Heplisav-B, with median postvaccination HBsAb levels of 114 IU/L. Patients with chronic obstructive pulmonary disease, chronic kidney disease, diabetes mellitus, immunomodulator use, or those on 2 or more of immunosuppressive medications were less likely to respond to Heplisav-B, though these findings were not statistically significant on a multivariate analysis aside from chronic kidney disease.
Conclusions
Heplisav-B, a 2-dose vaccine, is an effective vaccine for HBV in patients with IBD. In our study, its overall efficacy (78.3%) is greater than that reported for the presently available 3-dose vaccination (Engerix) in patients with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
ORCID-Profile: Joshua Y Kwon, Jana G Hashash
Zitieren
APA
Kwon, J. Y., Daoud, N. D., Hashash, J. G., Picco, M. F., & Farraye, F. A. (2023). Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac079
Vancouver
Kwon JY, Daoud ND, Hashash JG, Picco MF, Farraye FA. Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac079
BibTeX
@article{Kwon2023,
author = {Kwon, Joshua Y and Daoud, Nader D and Hashash, Jana G and Picco, Michael F and Farraye, Francis A},
title = {Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease},
journal = {Inflammatory Bowel Diseases},
year = {2023},
doi = {10.1093/ibd/izac079}
}
EUVIMED